GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » EV-to-FCF

Biosyent (Biosyent) EV-to-FCF : 14.96 (As of May. 02, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biosyent's Enterprise Value is $54.80 Mil. Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $3.66 Mil. Therefore, Biosyent's EV-to-FCF for today is 14.96.

The historical rank and industry rank for Biosyent's EV-to-FCF or its related term are showing as below:

BIOYF' s EV-to-FCF Range Over the Past 10 Years
Min: 6.85   Med: 19.03   Max: 82.94
Current: 15.33

During the past 13 years, the highest EV-to-FCF of Biosyent was 82.94. The lowest was 6.85. And the median was 19.03.

BIOYF's EV-to-FCF is ranked better than
64.97% of 511 companies
in the Drug Manufacturers industry
Industry Median: 22.28 vs BIOYF: 15.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), Biosyent's stock price is $6.3287. Biosyent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.394. Therefore, Biosyent's PE Ratio for today is 16.06.


Biosyent EV-to-FCF Historical Data

The historical data trend for Biosyent's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent EV-to-FCF Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.02 11.52 16.82 12.95 17.06

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.95 19.47 12.66 10.51 17.06

Competitive Comparison of Biosyent's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biosyent's EV-to-FCF falls into.



Biosyent EV-to-FCF Calculation

Biosyent's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=54.798/3.664
=14.96

Biosyent's current Enterprise Value is $54.80 Mil.
Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biosyent's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.3287/0.394
=16.06

Biosyent's share price for today is $6.3287.
Biosyent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.394.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biosyent EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biosyent's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019